This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Quarter ended Sep 2026: consolidated revenue up 31%, profit after tax nearly flat, exceptional gain
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated revenue from operations in the quarter ended 30 September 2026 rose 31.1% to Rs 58,052.58 lakh from Rs 44,288.16 lakh a year earlier, while consolidated profit after tax edged up 3.6% to Rs 9,512.58 lakh from Rs 9,179.75 lakh. EBITDA margin narrowed year on year. The quarter included a Rs 956.21 lakh exceptional gain from derecognition of contingent consideration. Acquisition goodwill was restated after purchase-price finalisation.
Revenue growth helps, but nearly flat profit after tax and a lower EBITDA margin signal pressure; the exceptional gain weakens profit quality.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹580.5 Cr | ₹443.9 Cr | +30.8% |
| Operating profit | ₹95.37 Cr | ₹86.78 Cr | +9.9% |
| Profit after tax | ₹95.13 Cr | ₹91.80 Cr | +3.6% |
| EBITDA margin | 25.3% | 25.8% | −0.5 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.